Heart failure is a major and ever-growing health problem affecting an estimated 5.8 million Americans with about half a million new cases every year. There are limited therapeutic options for…
Heart disease is the number one cause of morbidity and mortality in the US. With an estimated 1.5 million new or recurrent myocardial infarctions, the total economic burden on our…
Autophagy is the cells mechanism for breaking down and recycling proteins. Danon disease is an inherited disorder of autophagy. Patients with this disease have major abnormalities in heart and skeletal…
An estimated 16.3 million Americans suffer from coronary heart disease. Every 25 seconds, someone has a coronary event and every minute, someone dies from one. Treatment for coronary heart disease…
Critical limb ischemia (CLI) represents a significant unmet medical need without any approved medical therapies for patients who fail surgical or angioplasty procedures to restore blood flow to the lower…
This application seeks to bring to the clinic a new treatment for myocardial disease based on human embryonic stem cell (hESC) derived cardiomyocytes. hESC-cardiomyocytes have the unique potential to address…
Patients with end-stage heart failure (ESHF) have a 2-year survival rate of 50% with conventional medical therapy. This dismal survival rate is actually significantly worse than patients with AIDS, liver…
California's Stem Cell Agency (CIRM) has catalyzed the growth of stem cell research by helping recruit scientists to the state. In this video, we feature Dr. Todd McDevitt, a leading biomedical…
Watch this Google Hangout to learn about recent progress in developing stem cell therapies for heart disease. Hear from stem cell clinical trial participant Fred Lesikar, stem cell experts Dr.…
Title: Lessons learned from Phase 1 trial of heart-derived stem cells as we move into Phase 2 Speaker: Eduardo Marbán, M.D., Ph.D. Founder and Chairman of Scientific Advisory Board, Capricor,…
Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
